Ozempic users may be able to take fewer doses than usual and still maintain their weight loss and health improvements, according to a recent study. This finding could have significant implications for the long-term use of GLP-1 treatments like semaglutide (Ozempic and Wegovy).
The study, conducted by doctors at Scripps Health, involved 30 participants who were offered the chance to taper their medication after reaching a weight plateau. The results showed that most people maintained their BMI and improved health markers, even when dosing as little as once every two months. This suggests that reduced dosing could be a viable strategy for long-term GLP-1 use, potentially making it more affordable and less burdensome.
The authors of the study, published in the journal Obesity, suggest that structured de-escalation could reduce treatment burden without sacrificing efficacy. However, they also acknowledge that larger studies are needed to confirm these findings and address concerns about indefinite therapy, lower healthcare costs, and supply constraints.
One interesting observation is that some participants who started tapering off their medication switched back to their original schedule after regaining weight. This highlights the need for further research and personalized approaches to tapering.
In conclusion, this study provides a promising insight into the potential of reduced dosing for GLP-1 treatments. It opens up new possibilities for long-term use and could help people manage their weight loss and health improvements more effectively. However, more research is needed to fully understand the implications and ensure the safety and effectiveness of this approach.
